Grifols, S.A. (GRFS) vs Novo Nordisk A/S (NVO)
- Grifols, S.A. GRFS 7.64 +1.33%
- Novo Nordisk A/S NVO 38.83 −0.99%
Grifols, S.A. and Novo Nordisk A/S are both Drug Manufacturers General companies. Novo Nordisk A/S is the larger, with a market value of $131.2B against $2.0B — 67.3× the size. Grifols, S.A. trades at the lower P/E: 8.5× against 9.5×. Grifols, S.A. grew revenue faster over the last twelve months: 16.0% against 13.2%. Novo Nordisk A/S has the higher net margin (35.5% vs 5.54%) and the higher return on invested capital (28.7% vs 0.00%). Both pay a dividend; Novo Nordisk A/S yields more (4.63% vs 1.24%). Across the 23 metrics below, Novo Nordisk A/S leads on 13 and Grifols, S.A. on 10.
Valuation
Profitability
| Metric | GRFS | NVO | Drug Manufacturers General median |
|---|---|---|---|
| Gross margin | 37.45% | 80.73% | 72.77% |
| Operating margin | 16.43% | 43.36% | 18.77% |
| Net margin | 5.54% | 35.47% | 8.27% |
| Free cash flow margin | 0.00% | 14.79% | 17.18% |
| Return on equity | 0.00% | 60.84% | 5.87% |
| Return on assets | 0.00% | 22.00% | 2.57% |
| Return on invested capital | 0.00% | 28.67% | 6.11% |
Growth
Health
Dividend
Size
Any metric, up to five companies and an Excel export Powerpack